Rice Hall James & Associates LLC Sells 2,089 Shares of AxoGen, Inc. (NASDAQ:AXGN)

Rice Hall James & Associates LLC lowered its stake in shares of AxoGen, Inc. (NASDAQ:AXGN) by 1.1% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 192,180 shares of the medical equipment provider’s stock after selling 2,089 shares during the period. Rice Hall James & Associates LLC’s holdings in AxoGen were worth $2,694,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its holdings in shares of AxoGen by 8.6% in the first quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock worth $168,000 after buying an additional 1,651 shares during the last quarter. Roubaix Capital LLC purchased a new position in AxoGen during the first quarter valued at approximately $351,000. Lazard Asset Management LLC lifted its holdings in AxoGen by 30.1% during the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 2,671 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in AxoGen by 8.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider’s stock valued at $240,000 after purchasing an additional 2,204 shares in the last quarter. Finally, First Light Asset Management LLC lifted its holdings in AxoGen by 177.0% during the first quarter. First Light Asset Management LLC now owns 765,886 shares of the medical equipment provider’s stock valued at $6,181,000 after purchasing an additional 489,397 shares in the last quarter. Institutional investors own 80.29% of the company’s stock.

Analyst Upgrades and Downgrades

AXGN has been the topic of several analyst reports. JMP Securities lifted their price target on shares of AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a report on Friday, August 9th. StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $15.00.

AxoGen Trading Down 0.4 %

AxoGen stock opened at $13.95 on Friday. The stock has a market cap of $611.43 million, a P/E ratio of -36.71 and a beta of 1.13. The company has a debt-to-equity ratio of 0.70, a current ratio of 3.51 and a quick ratio of 2.32. AxoGen, Inc. has a 1 year low of $3.56 and a 1 year high of $15.23. The firm’s 50 day moving average price is $13.65 and its 200-day moving average price is $9.81.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. The firm had revenue of $47.91 million for the quarter, compared to analysts’ expectations of $43.27 million. On average, equities analysts predict that AxoGen, Inc. will post -0.33 earnings per share for the current fiscal year.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.